Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "Paris"

141 News Found

Suven Pharma Q3FY22 PAT at Rs. 160.06 crore
News | February 08, 2022

Suven Pharma Q3FY22 PAT at Rs. 160.06 crore

Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.

Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
News | February 05, 2022

Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore

Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021

Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore
News | February 05, 2022

Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore

Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021

IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore
News | February 05, 2022

IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore

IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore
News | February 05, 2022

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore

Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021

Lupin Q3FY22 PAT at Rs 545.52 cr.
News | February 04, 2022

Lupin Q3FY22 PAT at Rs 545.52 cr.

Lupin has reported consolidated financial results for the period ended December 31, 2021

Pfizer Q3FY22 PAT at Rs 143.91 crore
News | February 04, 2022

Pfizer Q3FY22 PAT at Rs 143.91 crore

The company has reported standalone financial results for the period ended December 31, 2021.

Caplin Point Q3FY22 PAT at Rs 74.95 cr.
News | February 03, 2022

Caplin Point Q3FY22 PAT at Rs 74.95 cr.

Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.

Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.
News | January 31, 2022

Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.

Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
News | January 28, 2022

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021

Latest Stories

Quality Care India partners Intuitive to take robotic surgery beyond metros

Nova IVF Fertility expands in Kerala with acquisition of Craft Fertility

Novartis strikes $3 billion deal to acquire next-gen breast cancer drug

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging